Subject: Designation of National Institute of Health, Department of Medical Sciences, Miscellaneous Bacteriology Section, Ministry of Public Health, Thailand as WHO CC for Antimicrobial Resistance Surveillance and Training

I have the honor to inform you that after due consideration and following the designation process, the World Health Organization proposes to designate National Institute of Health, Department of Medical Sciences, Miscellaneous Bacteriology Section, Ministry of Public Health, Thailand as WHO CC for Antimicrobial Resistance Surveillance and Training. The proposed terms of reference and work plan of the Centre are enclosed for your kind perusal.

The World Health Organization will make available to the Centre relevant information and study material in connection with proposed collaborative activities. While the designation is for a period of four years, it can be revoked by either party by giving a notice of three months.

I am confident that designation of this new WHO Collaborative Centre will go a long way in strengthening efforts in this important area of work. I look forward to receiving your comments/concurrence on this proposal at your earliest convenience to enable us to complete the necessary formalities. We will assume that the proposal is acceptable to the Ministry if we do not receive any response within the next six weeks.

Yours truly,

[Signature]

Dr Poonam Khetrapal Singh
Regional Director

End: As above

cc: The Ministry of Foreign Affairs, Royal Thai Government, Sri Ayudhaya Road, Bangkok, Thailand
cc: The Director-General, Thailand International Development Cooperation Agency (TICA), Ministry of Foreign Affairs, 962 Krung Kasem Road, Bangkok, Thailand
cc: The Director, Department of Medical Sciences, Ministry of Public Health, Tiwanon Road, Nonthaburi, Thailand
cc and through: The WHO Representative to Thailand, Nonthaburi, Thailand
Collaborating Centres
DESIGNATION FORM

The designation form consists of three parts:

Part I - Institutional Profile
Part II - Terms of Reference (TOR)
Part III - Workplan

This designation form below, together with the Terms and conditions for WHO collaborating centres will serve as the agreement between the proposed institution and WHO if the designation as WHO collaborating centre is approved by WHO. Completion and submission of the designation form, however, does not guarantee that the designation will be approved.

Name of the University, Hospital, Research Institute, Academy or Ministry
Ministry of Public Health, National Institute of Health

Name of the Division, Department, Unit, Section or Area
Department of Medical Sciences, Miscellaneous Bacteriology Section

City
Nonthaburi

CC Reference Number
THA-71

Title
WHO Collaborating Centre for Antimicrobial Resistance Surveillance and Training

Part I - Institutional Profile

The majority of designations as WHO CC are given to a part (e.g. department, division, unit, etc) of an institution, as opposed to the institution as a whole. Example: the Department of Microbiology of the University of ABC. In those cases, when a question in the designation form refers to the "institution", please only provide information about the concerned part (e.g. the Department of Microbiology) of the institution and not about the institution as a whole (e.g. the University of ABC). Where information about the institution as a whole is being required, this will be clearly stated.

The term "WHO CC" means the (part of the) institution designated as a WHO collaborating centre while performing the agreed terms of reference and work plan with WHO (as opposed to the institution performing other activities outside the agreed terms of reference and workplan). Example: Department of Microbiology of the University of ABC, when working on activities included in this designation form and agreed with WHO.

A WHO CC is not a legal entity. The legal entity which controls and is responsible for the WHO CC is the institution or the ministry, academy, university, established research institute or hospital of which the institution forms part.

Address of the proposed institution

1.1 Street and number
Tivanond Road
1.2 City
Nonthaburi
1.3 State/Region/Canton/Province
Nonthaburi
1.4 Postal Code
11000
1.5 Country
THA
1.6 WHO Region
SEARO
1.7 Phone
(66-2) 589 9850
1.8 Fax
(66-2) 591 5449
1.9 Web site
http://narst.dmhc.moph.go.th

Staff of the proposed institution

1.10 Name of the director of the institution as a whole
Dr. Somchai Sangkitporn

1.11 - Name and email of the proposed heads of the WHO collaborating centre (Please note this information will be listed in the public database)
Collaborating Centres
DESIGNATION FORM

Salutation  First Name  Last Name  Email Address
Ms  Wantana  Paveen kittporn  wantana.p@dmsc.mail.go.th
Salutation  First Name  Last Name  Email Address

1.12 Please list the names of professional staff working at the proposed institution together with their professional qualifications (e.g. Dr John Smith MPH). Please do not include full resumes or biographies.
Dr. Aree Thattiyapong BSc(Med Tech), MSc(Trop Med), PhD(Bioscience)
Mr. Aekkawat Unahalekhakh BSc(Microbiology)

Sources of funding
Note: The reference to companies in this form includes trade associations and foundations closely associated with their commercial sponsors. The reference to "companies engaged in activities relating to tobacco" includes companies engaged in the manufacture, distribution and/or sale of tobacco or tobacco products and subsidiaries of such companies (including holding companies).

1.13 During the last two years, what percentage of the proposed institution's funding was core funding? Core funding refers to funding that is received by the proposed institution in a regular manner (e.g. a specific amount received annually from a secure source), as opposed to ad-hoc contributions that are received once or at irregular intervals.
over 75% regular (core) funding

1.14 Did over the last three years, does currently, or is there a prospect that, the institution as a whole will receive funds from one or more companies whose business activities are incompatible with WHO's work (e.g. companies engaged in activities relating to tobacco)?
Yes  No  ✔
If "Yes", please provide details (i.e. names of companies, their business activities, level of funding, for what such funding was, is being, or will be, used, together with an indication whether such funding has stopped (and if so, the year in which it stopped), or is current or prospective.

1.15 Does the proposed institution currently, or is there a prospect that the proposed institution will, receive funds from one or more companies that have, or may be perceived as having, a direct or indirect commercial interest in the activities being conducted by the proposed institution as part of its terms of reference as a WHO collaborating centre?
Yes  No  ✔
If "Yes", please provide details (i.e. names of companies, their business activities, level of funding, for what such funding is being, or will be, used, together with an indication whether such funding is current or prospective).

1.16 Does the proposed institution currently, or is there a prospect that the proposed institution will, perform research or other work commissioned by industry as part of its terms of reference as a WHO collaborating centre?
Yes  No  ✔
If "Yes", please provide details (i.e. description of the research or other work, names of companies by which the research or other work is being commissioned, the business activities of these companies, and a clarification of the amounts charged for this research or other work, i.e. whether these amounts are charged on a cost recovery basis or any other basis).

3/18/2014 6:23:21 AM
1.17 Does the proposed institution currently, or is there a prospect that the proposed institution will, receive unspecified funds from one or more companies which it is planning to use directly or indirectly for the implementation of the agreed terms of reference as a WHO collaborating centre?

Yes [✓] No [ ]

If "Yes", please provide details (i.e. the names of companies, their business activities, level of funding, for what such funding is being, or will be, used and whether the institution is dependent on the support of one or more of these companies for its continued operation).

1.18 Does the proposed institution currently, or is there a prospect that the proposed institution will, receive funding from one or more companies to support the salary of specific staff or posts working on the activities conducted as part of its terms of reference as a WHO collaborating centre?

Yes [✓] No [ ]

If "Yes", please provide details (i.e. names of companies, their business activities, level of funding, for which staff or what posts such funding is being, or will be, used, and the functions of such staff and/or posts).

1.19 Did over the last three years, does currently, or is there a prospect that, any staff of the institution designated to work on the activities of the WHO collaborating centre, including the proposed head(s) of the WHO collaborating centre, have any other interactions, affiliations or relations with, or any other personal, professional, financial or business interests in, one or more companies that could give rise, or be seen as giving rise, to a conflict of interest?

Such a conflict could exist:
(i) if the company has, or may be perceived as having, a direct or indirect commercial interest in all or part of the activities being conducted by the proposed institution as a WHO collaborating centre;
(ii) if the business activities of the company are incompatible with WHO's work (e.g. companies engaged in activities relating to tobacco); or if the company has (or may be seen as having) a vested interest in exerting influence on the activities of the WHO collaborating centre and/or their outcome.

Interactions, affiliations, relations with, or other personal, professional, financial or business interests include, but are not necessarily limited to, collaborative projects or initiatives, employment, consultancy, investment interests (e.g. stocks, bonds, stock options, other securities, but not mutual funds, pension funds or similar investments that are broadly diversified), commercial business interests (e.g., proprietorships, partnerships, joint ventures), patents, trademarks, or copyrights (including pending applications), proprietary know-how in a substance, technology or process.

Yes [✓] No [ ]

If "Yes", please provide details (i.e. names of the companies involved, their business activities, the nature of the interactions, affiliations, relations, or other personal, professional, financial or business interests, and the value of or income generated through such the interactions, affiliations, relations or other interests, together with an indication whether the interactions, affiliations, relations, or other personal, professional, financial or business interests in question have stopped (and if so, the year in which they stopped), or whether they are current or prospective).
Institutional characteristics

1.20 What type of entity is the proposed institution?
Public
Please provide details

1.21 What type of organization is the proposed institution?
Non profit entities
Please provide details

1.22 The proposed institution is or forms part of a
Ministry
Please provide details

1.23 Please attach a current organizational chart (1 page) of the institution as a whole, including its sub-parts such as divisions, departments, sections, unit or areas (whichever structure applies), indicating the part proposed as WHO collaborating centre.
WHOCC.pdf

1.24 Number of years the institution as a whole is in operation
more than 10 years

1.25 Number of years the proposed institution is in operation
more than 10 years

1.26 Please list major facilities and any specialized equipment available to the proposed institution (e.g. laboratories, training facilities, documentation centre), if applicable. Please do not list general office space or standard office equipment.
WHO Polio Regional Reference Laboratory in South-East Asia Region
WHO Measles Regional Reference Laboratory in South-East Asia Region
WHO Regional Influenza Reference Laboratory for the South-East Asia Region
DNA sequencer, Real-time PCR thermocycler, Vitek automate identification, Automate DNA extraction

1.27 Does the proposed institution currently establish a smoke-free environment across its premises, which can be illustrated either through a documented institutional/departmental policy or through the existence of national/local smoke-free legislation? The smoke-free environment must apply to all indoor workplaces and public places of the institution's premises, and must entail a complete ban of smoking indoors and no areas designated for smoking.
No

☑ The proposed institution agrees with the following Terms and conditions for WHO collaborating centres.
Part II - Terms of Reference (TOR)

Please include the proposed terms of reference for the future collaboration between the proposed institution and WHO, as discussed prior to completing this form. In most cases, 1-3 TOR will be sufficient to provide a high-level framework of the future collaboration. For redesignations, the current terms of reference is automatically prefilled but can be revised as appropriate.

For detailed instructions on how to fill in this section please click on the link provided at the top of the form.

**TOR 1**
To assist WHO in collecting, collating, analyzing and disseminating information of antimicrobial resistance status nationally and internationally.

**TOR 2**
On specific request, assist WHO to provide technical assistance to Member States in establishing antimicrobial resistance surveillance.

**TOR 3**
To assist WHO to initiate international external quality assessment scheme for health laboratories.

**TOR 4**
To assist WHO to standardize the microbiological and antimicrobial testing among participating laboratories in the surveillance program and to transfer appropriate technology, educate and train lab personnel in the surveillance program.
### Collaborating Centres
#### DESIGNATION FORM

#### Part III - Workplan

<table>
<thead>
<tr>
<th>Activity ID</th>
<th>Activity title</th>
<th>Link to TOR</th>
<th>Name(s) of responsible staff at the institution</th>
<th>Type of activity</th>
<th>Description of the activity and how it is implemented</th>
<th>Expected deliverables</th>
<th>WHO Deliverable (Top Task)</th>
<th>Name(s) of funding sources</th>
<th>Activity timeframe</th>
<th>This activity has been specifically developed for the workplan of the WHO collaborating centre and does not constitute a standard activity of the institution without WHO involvement.</th>
</tr>
</thead>
<tbody>
<tr>
<td>20181</td>
<td>Improvement of documentation center</td>
<td>TOR1</td>
<td>Mr. Aekkawat Unahalekhaka</td>
<td>Information dissemination</td>
<td>upgrade sdata server in both hardware and software</td>
<td>coordinate and combine computerized system to Information System Center of DMSc</td>
<td>Alert system for AMR organism</td>
<td>prevention and containment of AMR</td>
<td>Government</td>
<td>1-2 years</td>
</tr>
</tbody>
</table>

#### Activity

<table>
<thead>
<tr>
<th>Activity ID</th>
<th>Activity title</th>
<th>Link to TOR</th>
<th>Name(s) of responsible staff at the institution</th>
<th>Type of activity</th>
<th>Description of the activity and how it is implemented</th>
<th>Expected deliverables</th>
<th>WHO Deliverable (Top Task)</th>
<th>Name(s) of funding sources</th>
<th>Activity timeframe</th>
<th>This activity has been specifically developed for the workplan of the WHO collaborating centre and does not constitute a standard activity of the institution without WHO involvement.</th>
</tr>
</thead>
<tbody>
<tr>
<td>20197</td>
<td>Workshop for detection of AMR bacteria and update knowledge on new emerging AMR</td>
<td>TOR4</td>
<td>Dr. Wantana Paveenkittiporn</td>
<td>Development and application of appropriate technology</td>
<td>Organize training on AMR bacteria detection, especially the new emerging AMR bacteria at the National levels. The developed or modified detection by molecular technology as well as simplified screening for enzyme producing AMR organisms will be transferred to the member hospitals.</td>
<td>resistant gene detection by molecular technology as well as simplified screening method for enzyme producing AMR organisms</td>
<td>prevention and containment of AMR bacteria</td>
<td>expect from Government</td>
<td>once a year</td>
<td>--------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Activity ID</td>
<td>Activity title</td>
<td>Link to TOR</td>
<td>Name(s) of responsible staff at the institution</td>
<td>Type of activity</td>
<td>Description of the activity and how it is implemented</td>
<td>Expected deliverables</td>
<td>WHO Deliverable (Top Task)</td>
<td>Name(s) of funding sources</td>
<td>Activity timeframe</td>
<td>This activity has been specifically developed for the workplan of the WHO collaborating centre and does not constitute a standard activity of the institution without WHO involvement.</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>20198</td>
<td>Training of laboratory-based surveillance and quality assurance on AMR</td>
<td>TOR2, TOR3</td>
<td>Dr Wantana Paveenkitiporn and Mr Aekkawat Unahalekhaka</td>
<td>Implementation of WHO programmes and activities at country level</td>
<td>Provide training on AMR surveillance programme.</td>
<td>Knowledge on laboratory-based surveillance programme for AMR</td>
<td>Establishment of regional AMR surveillance network</td>
<td>Expect from Government</td>
<td>1-3 years</td>
<td></td>
</tr>
</tbody>
</table>